These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 20108359

  • 1. Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP-treated common marmosets.
    Tayarani-Binazir KA, Jackson MJ, Rose S, Olanow CW, Jenner P.
    Mov Disord; 2010 Feb 15; 25(3):377-84. PubMed ID: 20108359
    [Abstract] [Full Text] [Related]

  • 2. Pardoprunox reverses motor deficits but induces only mild dyskinesia in MPTP-treated common marmosets.
    Johnston LC, Jackson MJ, Rose S, McCreary AC, Jenner P.
    Mov Disord; 2010 Oct 15; 25(13):2059-66. PubMed ID: 20721904
    [Abstract] [Full Text] [Related]

  • 3. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disability.
    Iravani MM, Tayarani-Binazir K, Chu WB, Jackson MJ, Jenner P.
    J Pharmacol Exp Ther; 2006 Dec 15; 319(3):1225-34. PubMed ID: 16959959
    [Abstract] [Full Text] [Related]

  • 4. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
    Hansard MJ, Smith LA, Jackson MJ, Cheetham SC, Jenner P.
    Mov Disord; 2004 Jan 15; 19(1):15-21. PubMed ID: 14743355
    [Abstract] [Full Text] [Related]

  • 5. The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets.
    Rose S, Jackson MJ, Smith LA, Stockwell K, Johnson L, Carminati P, Jenner P.
    Eur J Pharmacol; 2006 Sep 28; 546(1-3):82-7. PubMed ID: 16925991
    [Abstract] [Full Text] [Related]

  • 6. The partial dopamine agonist pardoprunox (SLV308) administered in combination with l-dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosets.
    Tayarani-Binazir K, Jackson MJ, Rose S, McCreary AC, Jenner P.
    Exp Neurol; 2010 Dec 28; 226(2):320-7. PubMed ID: 20843474
    [Abstract] [Full Text] [Related]

  • 7. Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation.
    Smith LA, Tel BC, Jackson MJ, Hansard MJ, Braceras R, Bonhomme C, Chezaubernard C, Del Signore S, Rose S, Jenner P.
    Mov Disord; 2002 Sep 28; 17(5):887-901. PubMed ID: 12360537
    [Abstract] [Full Text] [Related]

  • 8. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
    Pearce RK, Banerji T, Jenner P, Marsden CD.
    Mov Disord; 1998 Mar 28; 13(2):234-41. PubMed ID: 9539335
    [Abstract] [Full Text] [Related]

  • 9. Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates.
    Smith LA, Jackson MJ, Al-Barghouthy G, Rose S, Kuoppamaki M, Olanow W, Jenner P.
    Mov Disord; 2005 Mar 28; 20(3):306-14. PubMed ID: 15490461
    [Abstract] [Full Text] [Related]

  • 10. Continuous delivery of ropinirole reverses motor deficits without dyskinesia induction in MPTP-treated common marmosets.
    Stockwell KA, Virley DJ, Perren M, Iravani MM, Jackson MJ, Rose S, Jenner P.
    Exp Neurol; 2008 May 28; 211(1):172-9. PubMed ID: 18321484
    [Abstract] [Full Text] [Related]

  • 11. Switching from levodopa to the long-acting dopamine D2/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates.
    Smith LA, Jackson MJ, Johnston L, Kuoppamaki M, Rose S, Al-Barghouthy G, Del Signore S, Jenner P.
    Clin Neuropharmacol; 2006 May 28; 29(3):112-25. PubMed ID: 16772809
    [Abstract] [Full Text] [Related]

  • 12. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
    Kanda T, Jackson MJ, Smith LA, Pearce RK, Nakamura J, Kase H, Kuwana Y, Jenner P.
    Exp Neurol; 2000 Apr 28; 162(2):321-7. PubMed ID: 10739638
    [Abstract] [Full Text] [Related]

  • 13. Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure.
    Smith LA, Jackson MJ, Hansard MJ, Maratos E, Jenner P.
    Mov Disord; 2003 May 28; 18(5):487-95. PubMed ID: 12722161
    [Abstract] [Full Text] [Related]

  • 14. The dopamine D(2) receptor partial agonist aplindore improves motor deficits in MPTP-treated common marmosets alone and combined with L-dopa.
    Jackson MJ, Andree TH, Hansard M, Hoffman DC, Hurtt MR, Kehne JH, Pitler TA, Smith LA, Stack G, Jenner P.
    J Neural Transm (Vienna); 2010 Jan 28; 117(1):55-67. PubMed ID: 19809864
    [Abstract] [Full Text] [Related]

  • 15. The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmoset.
    Tayarani-Binazir KA, Jackson MJ, Fisher R, Zoubiane G, Rose S, Jenner P.
    Eur J Pharmacol; 2010 Jun 10; 635(1-3):109-16. PubMed ID: 20303948
    [Abstract] [Full Text] [Related]

  • 16. The administration of entacapone prevents L-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates.
    Zubair M, Jackson MJ, Tayarani-Binazir K, Stockwell KA, Smith LA, Rose S, Olanow W, Jenner P.
    Exp Neurol; 2007 Dec 10; 208(2):177-84. PubMed ID: 17935716
    [Abstract] [Full Text] [Related]

  • 17. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
    Pearce RK, Jackson M, Smith L, Jenner P, Marsden CD.
    Mov Disord; 1995 Nov 10; 10(6):731-40. PubMed ID: 8749992
    [Abstract] [Full Text] [Related]

  • 18. The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP-treated and levodopa-primed common marmosets.
    Pearce RK, Smith LA, Jackson MJ, Banerji T, Scheel-Krüger J, Jenner P.
    Mov Disord; 2002 Sep 10; 17(5):877-86. PubMed ID: 12360536
    [Abstract] [Full Text] [Related]

  • 19. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease.
    Hauser RA, McDermott MP, Messing S.
    Arch Neurol; 2006 Dec 10; 63(12):1756-60. PubMed ID: 17172616
    [Abstract] [Full Text] [Related]

  • 20. Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.
    Hill MP, Ravenscroft P, Bezard E, Crossman AR, Brotchie JM, Michel A, Grimée R, Klitgaard H.
    J Pharmacol Exp Ther; 2004 Jul 10; 310(1):386-94. PubMed ID: 15004218
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.